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OBJECTIVES: To evaluate medical and pharmacy costs associated with 
breakthrough pain (BTP) in a commercially-insured population with chronic, 
cancer-related pain. METHODS: The National Breakthrough Pain Survey studied 
a large commercially-insured population using claims data and structured 
interviews to assess the prevalence, characteristics, and impact of BTP. Adult 
patients with ≥2 medical claims at an interval ≥3 months with an ICD-9-CM code 
indicating a chronic pain condition (cancer or noncancer) and ≥3 opioid 
prescription claims consistent with chronic use were eligible. Patients were 
called and interviewed after providing consent; those verifying cancer pain were 
included in this sub-analysis. All-cause medical and pharmacy costs in 2010 US 
dollars were determined from administrative claims data for the 12-month 
period before the survey date. Generalized linear models with gamma 
distribution were constructed because of the skewed nature of the cost data. 
RESULTS: A total of 2198 patients were interviewed, 1279 had controlled 
persistent pain, and 145 of the latter group had cancer pain. Of those with cancer 
pain, BTP was reported by 77.2% (BTP, 112; no BTP, 33). Mean (SD) total annual 
health care costs for patients with and without BTP were $84,049 ($129,279) and 
$77,926 ($98,785), respectively. Costs in patients with BTP were 28.6% higher than 
patients without BTP (P=0.3211) after controlling for health plan, patient 
demographics, comorbidities, history of prior surgery, neuropathic pain, baseline 
pain severity, treatment by a pain specialist, and patient-reported pain 
interference. Mean (SD) total annual pharmacy costs for patients with BTP were 
$20,088 ($35,406) versus $9,939 ($9,715) for patients without BTP. Patients with 
BTP had pharmacy costs that were 81.7% higher than patients without BTP 
(P=0.0265) after controlling for the above variables. CONCLUSIONS: In a 
commercially-insured population, cancer patients with controlled, persistent 
pain and BTP had higher total health care and pharmacy costs than cancer 
patients with controlled, persistent pain without BTP.  
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OBJECTIVES: In the United States (US), approximately 862 patients have 
haemophilia with inhibitors. Inpatient hospitalization is often required for 
treatment, which can lead to significant costs to hospitals, depending on the 
cause for hospitalization, and the associated length of stay and hospital resource 
use. Variations in inpatient costs may also depend on patient inhibitor status to 
Factor VIII and the need for treatment with Factor VIII bypassing agents. A US 
hospital-based economic model was developed to estimate inpatient costs for 
on-demand treatment of bleeds of hemophilia patients with inhibitors and to 
quantify potential cost savings. METHODS: An Excel-based model patterned the 
inpatient care associated with use of currently available bypassing agents: 
activated prothrombin complex concentrate (pd-aPCC) and recombinant Factor 
VIIa (rFVIIa) utilizing treatment-specific resource use, service and pharmacy 
costs, and source admission estimates based on a retrospective analysis of the 
Premier Perspective™ Database (1,218 inpatient stays with an ICD-9 diagnosis of 
hemophilia A identified from 2003-2008). RESULTS: Within the Premier analysis, 
from 2003-2008 there were 4,560 male inpatient discharges (unweighted) with a 
Hemophilia A diagnosis. Of these, 252 showed use of a bypassing agent after 
excluding patients with OR charges and patients with inpatient stays with 
charges for both rFVIIa and pd-aPCC. The final weighted sample sizes was 1,218 
inpatient stays. In the base-case analysis, average per-patient costs associated 
with the inpatient treatment of hemophilia with inhibitors were slightly lower 
with rFVIIa as compared with pd-aPCC ($78,086 vs. $78,141). CONCLUSIONS: Fast 
bleed resolution may confer significant inpatient cost savings through 
reductions in length of stay and duration of bypass agent treatment. Thus, rFVIIa 
can reduce overall treatment costs and reduce indirect costs since fewer 
resources are required, which reduces the economic burden of haemophilia on 
society. More comparative studies of these agents for on-demand treatment in 
the inpatient setting are still needed.  
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OBJECTIVES: Anti-inflammatory drugs are widely used in the post-operative 
analgesia. This study aims to compare acute post-surgical pain management 
costs and resource utilization with parecoxib versus ketoprophene, ketorolac, 
and tenoxicam from the perspective of Brazilian private hospitals. METHODS: A 
cost-minimization analysis was performed to compare intravenous parecoxib 
40mg/day (PB), and parecoxib 40mg/day in bolus (PBbl) versus ketoprophene 
100mg/day generic (KPg) and branded (KPb), ketorolac 30mg/day generic (KLg) 
and branded (KLb), and tenoxicam 40mg/day generic (TNg) and branded (TNb), in 
a 3-day hospital stay after an orthopedic surgery. Direct medical costs included 
drug acquisition, nursing fees to administration, infusion supplies, 
complications associated to treatment and adverse event management 
(constipation related to opioid rescue medication, antacid and antiemetic drugs, 
gastrointestinal and surgical-wound bleedings). Resource utilization was 
estimated through literature review and expert opinion. Unit costs were obtained 
from Brazilian official price lists (2012 USD values) for each cost component. 
RESULTS: PBbl was the least costly treatment, with overall costs per patient of 
80.82USD, versus 117.92USD, 173.29USD, 182.56USD, 126.86USD, 133.39USD, 
125.27USD, and 131.67USD, for PB, KPg, KPb, KLg, KLb, TNg, and TNb, 
respectively. Incremental costs of comparators driven by surgical wound and 
gastrointestinal bleeding was responsible for 38.99USD or 22.5%, 21.4%, 30.7%, 
29.2%, 31.1%, and 29.6% with KPg, KPb, KLg, KLb, TNg, and TNb, respectively. No 
bleeding was reported for parecoxib. Adverse event management (antacid, 
antiemetic, constipation) was responsible for 6.37USD(7.9%), 6.37USD(5.4%), 
11.34USD(6.5%), 11.34USD(6.2%), 13.31USD(10.5%), 13.31USD(10.0%), 
8.74USD(7.0%), and 8.74USD(6.6%) with PBbl, PB ,KPg, KPb, KLg, KLb, TNg, and 
TNb, respectively. Drug acquisition, fees and supplies were responsible for 
74.45USD(92.1%), 111.5USD(94.6%), 122.96USD(71.0%), 132.24USD(72.4%), 
74.56USD(58.8%), 81.09USD(60.8%), 77.53USD(61.9%), and 83.93USD(63.7%) with 
PBbl, PB, KPg, KPb, KLg, KLb, TNg, and TNb, respectively. CONCLUSIONS: 
Parecoxib exhibited a cost-saving profile over branded or generic ketoprophene, 
ketorolac, and tenoxicam in post-surgical pain management, from the private 
hospital perspective in Brazil.  
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OBJECTIVES: Estimate the potential impact of opioid analgesics formulated with 
tamper resistant technologies (TRT) on drug acquisition and abuse treatment 
costs in a managed health plan through a budget impact model. METHODS: A 
model was developed to determine the impact of TRT therapy on opioid drug 
costs and abuse treatment costs for a hypothetical health plan of 1 million 
members. Claims analysis from the Thomson Reuters Commercial Encounters 
and Medicare Supplemental database was used to obtain the number of patients 
on low dose oxycodone therapy, annual days supply, prevalence of opioid abuse 
and annual abuse-related treatment costs. Patient willingness to continue TRT 
therapy was obtained from a clinical trial. Patients continuing TRT therapy were 
assumed to be non-abusers. Pricing assumptions were $2.67 (WAC) for a newly 
approved immediate release TRT and $0.16 for generic low dose oxycodone. A 
sensitivity analysis addressed the percentage of abusers placed on TRT therapy. 
RESULTS: Opioid abuse prevalence for patients on low dose oxycodone was 1.8%. 
Mean annual opioid abuse-related medical costs were $5,325. Mean annual days 
supply for patients with abuse claims was 169 days versus 40 days for patients 
with no claims. Thirty percent of patients were not willing to continue TRT 
therapy. With 20% of abuse patients placed on TRT therapy gradually over 24 
months, WAC drug acquisition costs increased 0.6% ($221,697 vs. $217,321) for 
the plan, while abuse treatment costs decreased 1.8% ($500,993 vs. $510,280) and 
total drug and treatment costs decreased 0.7%. With all abuse patients placed on 
TRT therapy, while there was a 3% increase in drug costs, there was a 9.1% 
reduction in abuse treatment costs and a decrease in total drug and treatment 
costs of 3.4%. CONCLUSIONS: TRT for patients with history of opioid abuse can 
potentially result in savings in abuse treatment costs and overall cost reductions.  
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OBJECTIVES: To discuss the amoxicillin use as an alternative to penicillin and 
compare its cost for antibiotic prophylaxis in children with SCD. METHODS: We 
searched for evidences in MEDLINE (Pubmed) with the terms “Anemia, Sickle 
Cell”[Mesh] and “Antibiotic Prophylaxis”[Mesh]. In a deterministic fashion, 
adopting the Brazilian public health system perspective, we did a budget impact 
analysis comparing amoxicillin to penicillin. The target population was 
estimated from hidroxyurea consumption in children with SCD and acquisition 
costs, both obtained from Ministry of Health databases (2012 values; exchange 
rate: US$ 1 = R$ 2.04). Data about dosage according to age and bodyweight were 
extracted from literature. RESULTS: A systematic review supports the use of 
penicillin prophylaxis in children with SCD, based on 3 RCTs (OR: 0.37; CI 95%: 
0.16 to 0.86), with no results for amoxicillin. Although, prospective studies show 
a low compliance of this approach (40 to 60%). Comparisons of amoxicillin to 
penicillin in other settings, as rheumatic fever prevention, demonstrate that 
once-daily oral amoxicillin is not inferior to twice-daily penicillin. We estimated 
a range of 143 to 325 children, less than 5 years old, with SCD as our target 
population. Assuming oral daily doses of 1500 mg (or 750 mg if bodyweight less 
than 30 kg) for amoxicillin and 500 mg (or 250 mg if bodyweight less than 20 kg) 
for penicillin, the annual acquisition costs of penicillin, oral solution, to treat this 
population can lead to expenses of US$ 41,161.93 to US$ 93,704.65. In contrast, 
expenses with amoxicillin, oral solution, would be a range of US$ 3,019.94 to US$ 
6,863.49. CONCLUSIONS: As well as penicillin, amoxicillin seems to be a good 
option for preventing pneumococcal infection in children with SCD as its use 
could represent annual savings of US$ 38,141.99 to US$ 86,841.15 and the once-
daily administration could improve the prophylaxis compliance.  
